Anti-CdtB and anti-vinculin antibodies to diagnose irritable bowel syndrome in inflammatory bowel disease patients

Abstract Background Despite adequate treatment, a subgroup of patients with inflammatory bowel disease (IBD), including Crohn`s disease and ulcerative colitis, have persistent gastrointestinal symptoms that are not always related to mucosal damage. Recently, two autoantibodies, anti-CdtB and anti-vi...

Full description

Saved in:
Bibliographic Details
Main Authors: Luisa Leite Barros, Gabriela Leite, Walter Morales, Gillian M. Barlow, Matheus Freitas Cardoso de Azevedo, Alexandre de Sousa Carlos, Adérson Omar Mourão Cintra Damião, Mark Pimentel, Alberto Queiroz Farias
Format: Article
Language:English
Published: BMC 2024-12-01
Series:BMC Gastroenterology
Subjects:
Online Access:https://doi.org/10.1186/s12876-024-03509-z
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850136838297092096
author Luisa Leite Barros
Gabriela Leite
Walter Morales
Gillian M. Barlow
Matheus Freitas Cardoso de Azevedo
Alexandre de Sousa Carlos
Adérson Omar Mourão Cintra Damião
Mark Pimentel
Alberto Queiroz Farias
author_facet Luisa Leite Barros
Gabriela Leite
Walter Morales
Gillian M. Barlow
Matheus Freitas Cardoso de Azevedo
Alexandre de Sousa Carlos
Adérson Omar Mourão Cintra Damião
Mark Pimentel
Alberto Queiroz Farias
author_sort Luisa Leite Barros
collection DOAJ
description Abstract Background Despite adequate treatment, a subgroup of patients with inflammatory bowel disease (IBD), including Crohn`s disease and ulcerative colitis, have persistent gastrointestinal symptoms that are not always related to mucosal damage. Recently, two autoantibodies, anti-CdtB and anti-vinculin, were validated as post-infectious IBS (PI-IBS) markers, however there is limited evidence of its diagnostic role in IBD population. Methods Patients with more than 3 bowel movements/day and indication of colonoscopy were enrolled. Samples were collected at the time of colonoscopy for assessment of serum levels of anti-CdtB and anti-vinculin antibodies. Results A total of 160 subjects were included in 4 groups: active IBD (n = 44); quiescent IBD and chronic diarrhea IBD-IBS (n = 25); predominant-diarrhea IBS (n = 45) and controls (n = 46). The mean value of the optical density for anti-CdtB was 1.2 ± 0.65 in group 1, 1.27 ± 0.64 in group 2, 1.49 ± 0.47 in the group 3 and 1.6 ± 0.68 in group 4, p = 0.012. For anti-vinculin, optical densities were: 1.34 ± 0.78 in group 1, 1.46 ± 0.92 in group 2, 1.31 ± 0.79 in group 3 and 1.41 ± 0.86 for controls (p = 0.875). Using a cut-off of 1.56 for anti-CdtB, the positivity between groups was n = 10 (22.7%) in group 1, n = 9 (34.6%) in group 2, 19 (43.2%) in group 3, 21 (45.7%) in group 4 (p = 0.106). The positivity of anti-vinculin using a cut-off of 1.6 was n = 18 (40.9%) in group 1, n = 11 (42.3%), n = 15 (34.1%), n = 22 (47.8%) (p = 0.622). Conclusions Our findings show that anti-CdtB and anti-vinculin could not identify IBD-IBS patients or discriminate IBS-D from healthy controls.
format Article
id doaj-art-cc4a523605824fefa93ca337d050bbea
institution OA Journals
issn 1471-230X
language English
publishDate 2024-12-01
publisher BMC
record_format Article
series BMC Gastroenterology
spelling doaj-art-cc4a523605824fefa93ca337d050bbea2025-08-20T02:31:00ZengBMCBMC Gastroenterology1471-230X2024-12-012411810.1186/s12876-024-03509-zAnti-CdtB and anti-vinculin antibodies to diagnose irritable bowel syndrome in inflammatory bowel disease patientsLuisa Leite Barros0Gabriela Leite1Walter Morales2Gillian M. Barlow3Matheus Freitas Cardoso de Azevedo4Alexandre de Sousa Carlos5Adérson Omar Mourão Cintra Damião6Mark Pimentel7Alberto Queiroz Farias8Department of Gastroenterology, University of Sao Paulo School of MedicineMedically Associated Science and Technology (MAST) Program, Cedars-Sinai Medical CenterMedically Associated Science and Technology (MAST) Program, Cedars-Sinai Medical CenterMedically Associated Science and Technology (MAST) Program, Cedars-Sinai Medical CenterDepartment of Gastroenterology, University of Sao Paulo School of MedicineDepartment of Gastroenterology, University of Sao Paulo School of MedicineDepartment of Gastroenterology, University of Sao Paulo School of MedicineMedically Associated Science and Technology (MAST) Program, Cedars-Sinai Medical CenterDepartment of Gastroenterology, University of Sao Paulo School of MedicineAbstract Background Despite adequate treatment, a subgroup of patients with inflammatory bowel disease (IBD), including Crohn`s disease and ulcerative colitis, have persistent gastrointestinal symptoms that are not always related to mucosal damage. Recently, two autoantibodies, anti-CdtB and anti-vinculin, were validated as post-infectious IBS (PI-IBS) markers, however there is limited evidence of its diagnostic role in IBD population. Methods Patients with more than 3 bowel movements/day and indication of colonoscopy were enrolled. Samples were collected at the time of colonoscopy for assessment of serum levels of anti-CdtB and anti-vinculin antibodies. Results A total of 160 subjects were included in 4 groups: active IBD (n = 44); quiescent IBD and chronic diarrhea IBD-IBS (n = 25); predominant-diarrhea IBS (n = 45) and controls (n = 46). The mean value of the optical density for anti-CdtB was 1.2 ± 0.65 in group 1, 1.27 ± 0.64 in group 2, 1.49 ± 0.47 in the group 3 and 1.6 ± 0.68 in group 4, p = 0.012. For anti-vinculin, optical densities were: 1.34 ± 0.78 in group 1, 1.46 ± 0.92 in group 2, 1.31 ± 0.79 in group 3 and 1.41 ± 0.86 for controls (p = 0.875). Using a cut-off of 1.56 for anti-CdtB, the positivity between groups was n = 10 (22.7%) in group 1, n = 9 (34.6%) in group 2, 19 (43.2%) in group 3, 21 (45.7%) in group 4 (p = 0.106). The positivity of anti-vinculin using a cut-off of 1.6 was n = 18 (40.9%) in group 1, n = 11 (42.3%), n = 15 (34.1%), n = 22 (47.8%) (p = 0.622). Conclusions Our findings show that anti-CdtB and anti-vinculin could not identify IBD-IBS patients or discriminate IBS-D from healthy controls.https://doi.org/10.1186/s12876-024-03509-zInflammatory bowel diseaseIrritable bowel syndromeAnti-CdtBAnti-vinculin
spellingShingle Luisa Leite Barros
Gabriela Leite
Walter Morales
Gillian M. Barlow
Matheus Freitas Cardoso de Azevedo
Alexandre de Sousa Carlos
Adérson Omar Mourão Cintra Damião
Mark Pimentel
Alberto Queiroz Farias
Anti-CdtB and anti-vinculin antibodies to diagnose irritable bowel syndrome in inflammatory bowel disease patients
BMC Gastroenterology
Inflammatory bowel disease
Irritable bowel syndrome
Anti-CdtB
Anti-vinculin
title Anti-CdtB and anti-vinculin antibodies to diagnose irritable bowel syndrome in inflammatory bowel disease patients
title_full Anti-CdtB and anti-vinculin antibodies to diagnose irritable bowel syndrome in inflammatory bowel disease patients
title_fullStr Anti-CdtB and anti-vinculin antibodies to diagnose irritable bowel syndrome in inflammatory bowel disease patients
title_full_unstemmed Anti-CdtB and anti-vinculin antibodies to diagnose irritable bowel syndrome in inflammatory bowel disease patients
title_short Anti-CdtB and anti-vinculin antibodies to diagnose irritable bowel syndrome in inflammatory bowel disease patients
title_sort anti cdtb and anti vinculin antibodies to diagnose irritable bowel syndrome in inflammatory bowel disease patients
topic Inflammatory bowel disease
Irritable bowel syndrome
Anti-CdtB
Anti-vinculin
url https://doi.org/10.1186/s12876-024-03509-z
work_keys_str_mv AT luisaleitebarros anticdtbandantivinculinantibodiestodiagnoseirritablebowelsyndromeininflammatoryboweldiseasepatients
AT gabrielaleite anticdtbandantivinculinantibodiestodiagnoseirritablebowelsyndromeininflammatoryboweldiseasepatients
AT waltermorales anticdtbandantivinculinantibodiestodiagnoseirritablebowelsyndromeininflammatoryboweldiseasepatients
AT gillianmbarlow anticdtbandantivinculinantibodiestodiagnoseirritablebowelsyndromeininflammatoryboweldiseasepatients
AT matheusfreitascardosodeazevedo anticdtbandantivinculinantibodiestodiagnoseirritablebowelsyndromeininflammatoryboweldiseasepatients
AT alexandredesousacarlos anticdtbandantivinculinantibodiestodiagnoseirritablebowelsyndromeininflammatoryboweldiseasepatients
AT adersonomarmouraocintradamiao anticdtbandantivinculinantibodiestodiagnoseirritablebowelsyndromeininflammatoryboweldiseasepatients
AT markpimentel anticdtbandantivinculinantibodiestodiagnoseirritablebowelsyndromeininflammatoryboweldiseasepatients
AT albertoqueirozfarias anticdtbandantivinculinantibodiestodiagnoseirritablebowelsyndromeininflammatoryboweldiseasepatients